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Abstract:
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a common malignancy. 
While inflammation-related biomarkers influence patient survival after 
resection, it has not been known whether postoperative inflammations 
affects the survival of PDAC patients or not. 
Methods 
It was investigated whether the universal biomarkers on postoperative 
day (POD) 7 affect the survival of PDAC patients in the retrospective 
view, and univariate and multivariate analyses were performed via the 
Cox regression method.   
Results 
Overall, 108 consecutive patients underwent resection; 98 (90.7%) had 
T3 disease and 73 (67.6%) had lymph node metastases. Thirty-four 
patients (31.5%) experienced postoperative complications. Compared 
with preoperative values, the white blood cell count and C-reactive 
protein (CRP) level on POD 7 were significantly elevated (p<0.001 for 
both); conversely, the lymphocyte count was significantly reduced 
(p<0.001). Among 108 patients, 72 received adjuvant chemotherapy. 
The median overall survival was 21.0 months; the 5-year survival rate 
was 22.3%. On multivariate analysis, receiving adjuvant chemotherapy 
and low CRP levels on POD 7 (<7.6 mg/dL) were prognosticators of 
better survival. However, the CD classification was not a prognosticator 
of survival after resection. 
Conclusions 
Adjuvant chemotherapy and postoperative low CRP levels on POD 7 were 
prognosticators of better survival of PDAC patients after resection. 
Surgeons should be aware of managing postoperative infections, 
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Pancreatic ductal adenocarcinoma (PDAC) is a common malignancy, and the survival 
of patients with PDAC is poor worldwide. Although resection is the only treatment that 
results in prolonged cancer-free survival, pancreatic resection sometimes causes 
postoperative complications; in particular, pancreaticoduodenectomy has a high 
incidence of postoperative complications [1, 2]. Postoperative complications influence 
the survival of patients who undergo resection for PDAC [3, 4]. As the damage caused 
by postoperative complications varies, it is not possible to evaluate the damage caused 
by each complication. 
The Clavien-Dindo (CD) classification is commonly used to describe the severity 
of postoperative complications in various surgical areas; as it is a grading system 
developed via consensus, it is easy to evaluate the degree of postoperative 
complications using this classification system [5]. The degree of severity of 
postoperative complications is associated with the survival of cancer patients after 
resection because postoperative adjuvant chemotherapy can be postponed owing to 
immunosuppression due to inflammatory cytokinemia, cancer-cell progression due to 
growth factors, and immunomodulation due to alteration of the intestinal microbiome 
induced by antibiotic usage for a long period, among other causes.
































































However, the CD classification cannot be used to evaluate the exact changes in 
the severity of systemic inflammation. For example, grade II complications per the CD 
classification indicate the need for pharmacological treatment with drugs other than 
those allowed for grade I complications, and grade III complications are classified 
according to the need for surgical, endoscopic, or radiological intervention. However, it 
is unclear which treatment is less invasive for patients with intra-abdominal abscess 
after pancreatic resection: whether long-term antimicrobial treatment should be 
performed for grade II complications or immediate surgical or radiological intervention 
is needed for grade III complications. Therefore, the CD classification does not 
necessarily indicate the degree of systemic inflammation, and the severity of 
postoperative complications cannot be evaluated, considering the number of 
postoperative factors. 
Postoperative inflammatory biomarkers, observed within 7 postoperative days 
(POD), aid in the early diagnosis of complications after pancreatic surgery [6], and the 
median day on which inflammatory postoperative complications are diagnosed is POD 
9 [7]. Postoperative systemic inflammation is thought to promote tumor-cell progression 
because of immunosuppression via inflammatory cytokines, cancer-cell progression via 
growth factors, and immunomodulation induced by antibiotic usage for a long period, 
































































thereby resulting in postoperative adjuvant chemotherapy being postponed.  Therefore, 
our main hypothesis is that high C-reactive protein (CRP) on POD 7 would be 
associated with worse survival on multivariate analysis. 
Methods
We retrospectively analyzed the data of patients who underwent resection for PDAC at 
the Shiga University of Medical Science Hospital, Japan, between January 2011 and 
July 2019. The protocol of this study was approved by the ethics committee of the Shiga 
University of Medical Science (registration No. 29-171). We provided patients with the 
opportunity to opt out; however, the need for informed consent was waived because of 
the retrospective design of the study.
Patients
Patients with pancreatic adenocarcinoma who were resected at the Shiga University of 
Medical Science Hospital (SUMSH) between January 2011 and July 2019 were 
included. Resectability was determined by preoperative computed tomography, and the 
































































patients with distant metastases or major arterial invasion were not indicated resection. 
All the patients underwent en bloc resection with lymph node dissection. Portal vein 
resection was performed only when the portal vein adhered to and could not be freed 
from the tumor. Patients who underwent residual resection (R2 resection) were excluded. 
Pathological tumor staging was performed using the Union for International Cancer 
Control TNM classification system for malignant tumors (8th edition). The CD 
classification system consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb, and V). On the basis 
of the size of the population or th  focus of a study, the classification can consist of 5 
grades (I, II, III, IV, and V), as the “a” and “b” sub-classification can be removed [5]. 
Postoperative chemotherapy
Patients who underwent PDAC were informed about both the benefits and adverse 
effects of postoperative adjuvant chemotherapy after resection. Gemcitabine (1000 
mg/m2 × 3 × 6 courses) [8] was administered to patients in the first half of the study. In 
the latter half of the study, after the results of the JASPAC-1 study proved the 
superiority of S-1 compared to gemcitabine [9], S-1 (40 mg, 50 mg, or 60 mg according 
to the body surface area) was orally administered twice a day for 28 days, followed by a 
14-day rest, every 6 weeks [9].

































































Continuous data are reported as the mean (standard deviation); normally distributed data 
were evaluated using Student’s t-test. The two-tailed χ2 test and Fisher’s exact test were 
used to analyze of categorical data. To assess the prognostic significance of individual 
variables and to identify independent predictors of survival, univariate and multivariate 
analyses were performed via the Cox regression method. The cut-off values for white 
blood cell (WBC) and lymphocyt  counts and CRP and albumin levels were estimated 
using 25% percentiles. The analyses were performed with IBM SPSS®, version 22.0 
(IBM, Armonk, NY, USA). The Cox proportional hazards regression analysis was 
performed via a multivariable stepwise selection procedure. The survival analysis was 
performed according to the Kaplan-Meier method, and survival was compared using the 
log-rank test and generalized Wilcoxon test.  Statistical significance was defined as a 
P-value of <0.05.  
Results
A total of 108 consecutive patients underwent radical resection for PDAC, and all 
































































patients were included in the current study. Table 1 shows the characteristics of the 
patients with PDAC. Advanced PDAC was the most commonly observed PDAC type; 
98 patients (90.7%) had T3 tumors, and 73 patients (67.6%) had lymph node metastases. 
In addition, 35 patients (32.4%) required biliary drainage for obstructive jaundice. 
Among the 108 patients, only 8 patients (7.4%) had grade 2 disease per the modified 
Glasgow prognostic score (GPS). A total of 21 patients underwent neoadjuvant therapy. 
Table 2 shows the perioperative and postoperative characteristics of the patients. 
Pancreaticoduodenectomy was performed in 64 patients, distal pancreatectomy in 33, 
and total pancreatectomy in 11. All the patients underwent lymph node dissection. 
Thirty-four patients (31.5%) experienced postoperative complications by POD 30. 
However, no patients died or required re-admission within POD 30. 
Compared to the preoperative values, the WBC count and CRP level on POD 7 
were significantly elevated (p<0.001 for both); in contrast, the lymphocyte count was 
significantly reduced (p<0.001). Table 3 shows the comparison between the CD 
classification and inflammatory biomarkers. The WBC count was significantly higher in 
patients with grade IV complications than in those with grade I complications (p=0.027). 
There was no relationship between CRP level and the CD classification.  The CRP 
level of patients with grade III complications was significantly higher than patients with 
































































grade II complications (p<0.002; Fig. 1). When patients were classified into those with 
grade I/II complications and those with grade III/IV complications, the WBC count 
tended to be higher in patients with grade III/IV complications (p=0.067); however, the 
lymphocyte count, CRP level, and increasing WBC and CRP level were not 
significantly different (Table 3).
Among the 108 patients, 72 patients received adjuvant chemotherapy using 
gemcitabine or S-1. Adjuvant chemotherapy was initiated on a median of POD 49 
(range, 22–233).    
The median follow-up duration was 15 months. A total of 76 recurrence events 
and 69 deaths were observed. The median recurrence-free survival and overall survival 
were 12.0 months and 21.0 months, respectively. The 2-year recurrence-free survival 
rate and the 5-year survival rate were 29.5% and 22.3%, respectively. 
Preoperative laboratory examinations were not associated with overall survival 
after surgery.  To assess whether the survival of patients with PDAC, who underwent 
resection, was affected by the postoperative systemic factors reflecting the 
inflammatory status and the severity of postoperative complications distinguished using 
the CD classification, univariate and multivariate analyses were performed using the 
following factors: T factor (T0/1 or T2/3), lymph node metastasis (present or absent), 
































































neoadjuvant chemotherapy (performed or not performed), adjuvant chemotherapy 
(performed or not performed), the CD classification (grade I/II or grade III/IV), the 
WBC count on POD 7, the lymphocyte count on POD 7, and the albumin level on POD 
7. Table 4 shows the hazard ratio (HR) and 95% confidence interval (CI) of the factors 
associated with survival after resection of PDAC. The following factors were indicators 
of better survival on multivariate analysis using the Cox proportional hazard model: 
having received adjuvant chemotherapy and a low CRP level on POD 7 (<7.6 mg/dL). 
Moreover, T0/1 and a high lymphocyte count on POD 7 (>8.5 ×103 μL) tended to 
improve the survival of patients with PDAC. However, the CD classification was not a 
predictor of survival after PDAC resection. 
Figure 2 demonstrates the survival curve using Kaplan-Meyer method divided 
into 2 groups (CRP-low and presence of an adjuvant chemotherapy group versus 
CRP-high and no adjuvant chemotherapy group) based on the result of this multivariate 
analysis.  The survival curve were divergent between the two groups, and the 5-year 
survival rates were 29.3% and 19.4%, respectively (log-Rank; P=0.349, generalized 
Wilcoxon; P=0.143).  

































































Surgical resection is the only treatment method for curing PDAC, besides 
pancreatectomy is an aggressive procedure with a high incidence of postoperative 
complications [2, 10, 11]. The results of the current study demonstrate that a higher 
CRP level on POD 7 was associated with unfavorable survival in patients with PDAC 
who underwent pancreatectomy. Hence, postoperative systemic inflammation is thought 
to promote tumor-cell progression because of immunosuppression via inflammatory 
cytokines, cancer-cell progression via growth factors, and immunomodulation induced 
by antibiotic usage for a long period, thereby resulting in postoperative adjuvant 
chemotherapy being postponed. 
Inflammatory biomarkers have prognostic value for patients with PDAC, 
including CRP and albumin levels; lymphocyte, monocyte, neutrophil, and platelet 
counts; and their derivatives, including the GPS, modified GPS, 
lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and 
platelet-to-lymphocyte ratio [12-15].  CRP is useful in the evaluation of systemic 
inflammation and is an indicator of the postoperative course. CRP is the reactant 
synthesized in hepatocytes in the acute phase, and it is up-regulated by cytokines, such 
as interleukin-6, interleukin-8 [16], and tumor necrosis factor-α [17]. In addition, a 
































































preoperative elevated CRP level is associated with poor survival of patients with 
colorectal cancer [18]. Moreover, preoperative elevated levels of serum CRP are 
significantly associated with a reduction in lymphocyte percentages in peripheral blood, 
and it can be an indicator of impaired immunity in patients with colorectal cancer [18].
The lymphocyte count is widely used as an index of immunocompetence, and 
lymphocytes play a role in tumor immunity during the suppression of carcinogenesis. In 
the current study, multivariate analysis demonstrated that the lymphocyte count, not the 
WBC count on POD 7, tended to contribute to better survival. These results suggest that 
the lymphocyte count is a surrogate marker for subclinical anti-tumor activities of the 
host. However, future studies should clarify the mechanism of how the lymphocytes 
improve the survival of patients.
Albumin is used to evaluate the nutritional and immunological status of the host. 
Hypoalbuminemia is an independent predictor of severe adverse postoperative 
outcomes [10]. Correlation analysis showed that postoperative albumin levels are only 
negatively correlated with the WBC and neutrophil counts as well as the CRP level [19]. 
However, the albumin level can be replenished intentionally via the infusion of 
exogenous albumin; in addition, the incidence of complications and the 30-day 
mortality rate do not differ significantly according to the albumin level [19]. In the 
































































current study, the postoperative albumin level did not affect the postoperative survival 
of patients with PDAC. 
The occurrence of postoperative complications might inhibit the performance of 
adjuvant chemotherapy, which is a favorable factor for survival [3, 8, 9]. The results of 
multivariate analysis in the current study also revealed that postoperative adjuvant 
chemotherapy improved patient survival after resection. 
The limitations of this study include the small sample size as well as the 
single-institute, retrospective study design; however, postoperative adjuvant 
chemotherapy and management of postoperative inflammation were identified as 
predictors of survival of patients with PDAC who underwent resection. We evaluated 
the postoperative levels of biomarkers on POD 7; however, it is unknown if POD7 is 
the optimal timepoint.  Unfortunately, the number of patients with high CRP and no 
adjuvant chemotherapy was too small to prove our hypothesis statistically.  However, 
the Kaplan-Meier curve were divergent between groups (CRP-low and presence of 
adjuvant chemotherapy versus CRP-high and no adjuvant chemotherapy), and we think 
our hypothesis could be clarified with a larger sample size.  In conclusion, surgeons 
should be aware of managing postoperative infections, because a high 
postoperative CRP level is related with unfavorable survival.
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Figure 1. Relationship between the grade on the Clavien-Dindo classification and the white blood 
cell and lymphocyte counts as well as C-reactive protein level on postoperative day 7. *; p=0.027 
(none vs. grade IVa), **; p=0.002 (none vs. grade IIIa/b).  
Figure 2. The Kaplan-Meyer curve was shown divided into 2 groups (CRP-low and presence of 
adjuvant chemotherapy; solid line versus CRP-high and no adjuvant chemotherapy; break line), and 
2 curve is divergent, suggesting that the patients with CRP-high and no adjuvant chemotherapy had 
poor survival factors .  
































































Table 1.  The characteristics of patients 
 
Parameter 
    
Age (years old) * 68.5 (9.47) 
Gender (male/female) 63/45 
Body mass index (kg/m2) * 21.47 (3.85) 
Diabetes mellitus 46 (42.6%) 
Biliary drainage 35 (32.9%) 
T factor (0/1/2/3) 1/4/5/98 
N factor (0/1/2) 35/71/2 
Hemoglobin (g/dL) * 12.2 (1.68) 
WBC  (x10３μL) * 5.4 (1.59) 
Lymphocyte  (x10３μL) * 1.26 (1.508) 
Albumin (g/dL) * 3.6 (0.44) 
C-reactive protein (mg/dL) * 0.58 (1.11) 
modified Glasgow prognostic score (0/1/2) 93/7/8 
CEA   (ng/mL)** 4.00 (0.9, 30.4) 
CA19-9  (U/mL)** 79.00 (1, 3315) 
Preoperative chemo(radio)therapy 21 (19.4%) 
 
*; mean (standard deviation), **; median (range) 
WBC ;white blood cells, CEA; carcinoembryonic antigen, CA19-9; carbohydrate 
antigen 19-9,  




Operative procedures (PD/DP/TP) 64/33/11 
Portal vein resection (yes) 32 (29.6%) 
Operative time (min.) ** 486.5 (199, 853) 
Estimate blood loss (mL) ** 855.5 (20, 10208)  
Blood transfusion (yes) 32 (29.6%) 
WBC on POD7  (x10３μL) * 8.7 (3.15) 
Lymphocyte on POD7  (x10３μL) * 1.03 (0.43) 
Albumin on POD7   (g/dL) * 2.7 (0.40) 
C-reactive protein on POD7 (mg/dL) * 5.36 (3.90) 
The Clavien-Dindo classification  (grade I/II/IIIa/IIIb/IVa/V) 6/35/24/2/8/0 
Adjuvant chemotherapy (yes) 77 (71.3%) 
 
*; mean (standard deviation), **; median (range) 
PD;pancreaticoduodenectomy, DP; distalpancreatectomy, TP; total pancreatectomy,  
WBC ;white blood cells, POD; postoperative days 
  
Table 3.  The comparison inflammatory biomarkers divided into the categorized CD 
classification.   
   
      
 The CD classification p-value 
Grade 0/I/II Grade III/IV  
Preoperative examinations 
WBC  (x10３μL) 5.38 (1.59) 5.50 (1.57) .719 
Lymphocyte  (x10３μL) 1.55 (0.58) 1.62 (0.68) .569 
C-reactive protein  (mg/dL) .51 (1.14) .63 (1.06) .622 
Postoperative examinations on postoperative day 7 
WBC  (x10３μL) 8.27 (2.93) 9.55 (3.48) .067 
Lymphocyte  (x10３μL) 1.05 (0.44) 0.99 (0.41) .554 
C-reactive protein  (mg/dL) 4.95 (4.23) 6.26 (2.92) .107 
 
CD; Clavien-Dindo 
WBC; white blood cell, 
 
  





                           Univariate analysis               Multivariate analysis      
Predictor HR 95% CI p-value HR 95% CI p-value 
T factor (0/1) .185 .026-1.353 0.094 .165 .023-1.208 .076 
LN metastases  1.309 .781-2.193 .307 1.30 .747-2.252 .356 
NAC 1.073 .574-2.006 .825 1.119 .591-2.119 .730 
Adjuvant chemotherapy .429 .259-.71 .001 .389 .227-.667 <.001 
CD classification (0/I/II) .770 .482-1.285 .317 .966 .555-1.681 .903 
WBC on POD7 (>9.9) 1.230 .724-2.089 .444 .990 .558-1.756 .972 
Lymphocyte on POD7 (>8.5) .777 .396-1.526 .464 .526 .255-1.086 .083 
CRP on POD7 (>7.6) 1.020 .962-1.083 .504 1.095 1.023-1.174 .009 
Albumin on POD7 (>2.5) .618 .358-1.065 .083 .610 .333-1.115 .108 
 
HR; hazard ratio (HR), CI; confidence interval,  
LN; lymph node, NAC; neoadjuvant chemotherapy, CD; Clavien-Dindo, WBC; white 
blood cell, POD; postoperative day, CRP; C-reactive protein 
 
